Biotage - Change in number of shares and votes
Biotage AB announced the issuance of 781,991 new ordinary shares in October 2021 as part of the acquisition of ATDBio Limited. This increased the total number of outstanding shares to 66,227,088, which includes 65,983,775 ordinary shares and 243,313 class C shares. The total voting rights now stand at 66,008,106.3, with a registered share capital of SEK 92,055,652.32. The company reported sales of 1,092 MSEK in 2020 and operates in over 70 countries.
- Completion of acquisition of ATDBio Limited.
- Increase in total shares to 66,227,088 indicating business expansion.
- None.
UPPSALA, Sweden, Oct. 29, 2021 /PRNewswire/ -- As previously announced, Biotage AB (publ) ("Biotage") has during October 2021 issued 781,991 new ordinary shares in connection with the acquisition of ATDBio Limited.
Prior to the issue, the total number of outstanding shares in Biotage amounted to 65,445,097 and the total number of votes amounted to 65,226,115.3. Through the issue the number of shares in Biotage has increased by 781,991 ordinary shares, corresponding to 781,991 votes. As of today, the last trading day of the month, the total number of registered and outstanding shares of Biotage amounts to 66,227,088, whereof 65,983,775 are ordinary shares and 243,313 are class C shares. As of today, the number of votes in Biotage amounts to 66,008,106.3, and the registered share capital amounts to SEK 92,055,652.32.
This information is information that Biotage AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 17.00 CET on 29 October 2021.
Contact persons:
Tomas Blomquist, CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com
About Biotage
Biotage is a Global Impact Tech Company committed to solving society's problems. We offer workflow solutions and products to customers in drug discovery and development, analytical testing and water and environmental testing.
Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.
Our customers span a broad range of market segments including pharmaceutical, biotech, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs approx. 485 people worldwide. The Group had sales of 1,092 MSEK in 2020 and our products are sold in more than 70 countries. Biotage's share (BIOT) is listed in the Mid Cap segment on the NASDAQ Stockholm.
Website: www.biotage.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/biotage/r/biotage---change-in-number-of-shares-and-votes,c3441519
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/biotage---change-in-number-of-shares-and-votes-301412024.html
SOURCE Cision AB
FAQ
What was the reason for Biotage's issuance of new shares in October 2021?
How many total shares does Biotage have after the new issuance?
What is Biotage's current registered share capital?
How many voting rights are there currently in Biotage?
What were Biotage's sales in 2020?
